ED Stock Recent News

ED LATEST HEADLINES

ED Stock News Image - prnewswire.com

NEW YORK , July 11, 2024 /PRNewswire/ -- Consolidated Edison, Inc. (Con Edison) (NYSE:ED) plans to report its 2nd Quarter 2024 earnings on August 1, 2024 after the market closes. Consolidated Edison, Inc. is one of the nation's largest investor-owned energy-delivery companies, with approximately $15 billion in annual revenues and $67 billion in assets.

prnewswire.com 2024 Jul 11
ED Stock News Image - zacks.com

Investors need to pay close attention to Consolidated Edison (ED) stock based on the movements in the options market lately.

zacks.com 2024 Jul 08
ED Stock News Image - zacks.com

Low beta stocks can offer stabilization when combined with high-beta stocks, providing a more balanced risk profile.

zacks.com 2024 Jul 05
ED Stock News Image - zacks.com

Both Consolidated Edison (ED) and PPL work efficiently and continue to provide reliable services to their customers.

zacks.com 2024 Jul 02
ED Stock News Image - zacks.com

Here is how Consolidated Edison (ED) and PPL (PPL) have performed compared to their sector so far this year.

zacks.com 2024 Jun 25
ED Stock News Image - zacks.com

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com 2024 Jun 24
ED Stock News Image - prnewswire.com

In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Phase 3 clinical study with new co-formulated bremelanotide plus a PDE5i in ED patients that do not respond to PDE5i monotherapy expected to start in the 1st half of calendar year 2025 CRANBURY, N.J. , June 20, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced the initiation of a Phase 2 clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i m

prnewswire.com 2024 Jun 20
ED Stock News Image - zacks.com

Con Ed (ED) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com 2024 Jun 19
ED Stock News Image - cnbc.com

Consolidated Edison's incoming chief financial officer is Kirk Andrews, who served as CFO of Midwest utility Evergy since 2021. Andrews will replace Robert Hoglund who plans to retire later in 2024.

cnbc.com 2024 Jun 10
ED Stock News Image - businesswire.com

KANSAS CITY, Mo.--(BUSINESS WIRE)--Evergy (NASDAQ: EVRG) announced today the pending departure of EVP and CFO Kirk Andrews, who will become CFO at Consolidated Edison (NYSE: ED).

businesswire.com 2024 Jun 10
10 of 50